By admin 
Phelan-McDermid syndrome is a rare neurodevelopmental genetic disorder, but its true rarity has long been underestimated. It is fundamentally caused by a deletion or a pathogenic mutation involving the SHANK3 gene located on the long arm of chromosome 22 (specifically, 22q13.33). The SHANK3 gene is a critical player in brain development, encoding a scaffolding protein essential for the structure and function of synapses – the junctions between neurons where information is transmitted. Disruption of this gene, whether through a missing segment of DNA or a specific alteration within its sequence, leads to a cascade of neurological and developmental challenges. Individuals with PMS typically present with a broad and variable range of medical, intellectual, and behavioral difficulties. A striking characteristic of the syndrome is its strong comorbidity with autism spectrum disorder (ASD); indeed, most people diagnosed with Phelan-McDermid syndrome also meet the diagnostic criteria for ASD. Changes affecting the SHANK3 gene are believed to account for a notable proportion, as much as one percent, of all autism spectrum disorder cases, highlighting its significant role in the etiology of autism.
The clinical manifestations of PMS are diverse, often presenting with global developmental delays, moderate to severe intellectual disability, and significant speech and language impairments. Motor delays, including hypotonia (low muscle tone) and difficulties with coordination, are also common. Beyond the core developmental and intellectual challenges, individuals with PMS frequently experience a range of medical issues, such as seizures, sleep disturbances, gastrointestinal problems, renal abnormalities, and lymphedema. Behavioral challenges can include repetitive behaviors, anxiety, mood dysregulation, and sometimes self-injurious behaviors, which further complicate daily living and require specialized care. The variability in presentation means that diagnosis can be challenging, as symptoms can overlap with other neurodevelopmental conditions, often leading to delayed or missed diagnoses. Before the advent of advanced genetic testing, many individuals with PMS may have been diagnosed with non-specific intellectual disability or autism without an identified genetic cause.
Genetic Data Reveal a Much Larger Population: A Paradigm Shift
To arrive at a more accurate estimate of how common this condition may truly be, Mount Sinai researchers embarked on an extensive, collaborative effort, working closely with leading genetic testing laboratories, academic medical centers, and prominent autism research programs. The team meticulously examined an unprecedented volume of data, specifically from nearly 180,000 individuals with autism who had undergone genetic testing. This large-scale approach allowed for a robust analysis that transcended the limitations of smaller, localized studies.
Their comprehensive analysis combined information from ten separate and diverse sources, ensuring a broad and representative dataset. These sources included major commercial genetic testing laboratories such as GeneDx, Labcorp, and Ambry Genetics, which process a vast number of clinical genetic tests. Additionally, data from significant research initiatives like the SPARK research study – one of the largest autism research cohorts globally – and the Autism Sequencing Consortium, a collaborative effort to identify genetic causes of autism, were incorporated. Contributions from several major children’s hospitals further enriched the dataset with real-world clinical patient information. This multi-pronged data collection strategy was critical for achieving a comprehensive picture of PMS prevalence across different populations and diagnostic pathways.
The researchers’ sophisticated analytical methodology extended beyond simply counting diagnosed cases. They meticulously accounted for several critical factors that could skew prevalence estimates, including undiagnosed cases within the broader population, inherent limits in the scope and accessibility of past and current genetic testing methodologies, and crucially, individuals with Phelan-McDermid syndrome who do not necessarily meet the full diagnostic criteria for autism. By extrapolating from the data of individuals with autism who had undergone genetic testing to the general population, and by making careful adjustments for these previously overlooked factors, the researchers arrived at a significantly revised prevalence estimate of 13.7 cases per 100,000 people. This figure translates to approximately 1 in 7,300 individuals.
This new estimate represents a monumental shift from previous figures, which often placed the prevalence of PMS closer to 1 in 100,000 or even rarer. The implications are profound: it suggests that more than 45,000 people in the United States alone could be living with Phelan-McDermid syndrome, many of whom are likely undiagnosed. This revelation not only highlights a substantial unmet diagnostic need but also paints a clearer picture of the scale of the challenge and the potential number of families who could benefit from a definitive diagnosis.
"The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," explained Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, a certified genetic counselor at the Seaver Autism Center, and the first author of the paper. Levy elaborated on the systemic barriers, noting that "Families may also face insurance barriers or may receive tests that do not adequately evaluate the SHANK3 gene." Historically, genetic testing was often limited to specific chromosomal analyses (like karyotyping) or targeted gene panels that might not have included SHANK3, leading to missed diagnoses. Even with the advent of chromosomal microarray analysis (CMA) and whole exome sequencing (WES), access remains uneven, and awareness among clinicians about the importance of comprehensive genetic evaluation for neurodevelopmental disorders is still evolving.
Why Genetic Testing Could Matter: Unlocking Precision Medicine
The researchers assert that broader and more equitable access to comprehensive genetic testing is not merely an academic ideal but a practical necessity that could significantly help identify countless individuals who currently lack a definitive diagnosis. This proactive approach to diagnosis is increasingly vital in the era of precision medicine.
"We recommend that every child with autism undergo genetic testing, because knowledge is power," urged Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, co-founder of the Autism Sequencing Consortium, and senior author of the paper. Dr. Buxbaum’s impassioned plea underscores the transformative potential of genetic diagnosis. For families, a genetic diagnosis provides clarity and understanding, replacing years of uncertainty with a concrete explanation for their child’s challenges. It can also alleviate the burden of diagnostic odysseys and multiple specialist visits.
Beyond personal understanding, these genetic findings are indispensable for advancing scientific discovery and therapeutic development. They allow researchers to design more targeted and effective clinical trials for potential therapies. When the genetic root cause of a condition is known, scientists can develop interventions that aim to correct the underlying molecular deficit, rather than simply managing symptoms. This precision medicine approach is at the forefront of neurological research. "I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries," Dr. Buxbaum predicted, signaling a profound sense of optimism for the future of PMS treatment. These treatments could range from gene therapies aiming to restore normal SHANK3 function to small molecule drugs that modulate downstream pathways affected by SHANK3 dysfunction.
The study received critical support from CureSHANK, a patient advocacy organization dedicated to PMS, and Neuren Pharmaceuticals, a biotechnology company focused on developing therapies for neurological disorders. This collaborative funding highlights the shared imperative to understand and address rare conditions. "Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative," stated Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals. Groth’s comments emphasize the moral obligation to ensure that those who stand to benefit from emerging therapies are first identified. "Patients cannot benefit from these advances if they never receive a diagnosis," she added, encapsulating the core message of the study.
New Treatments Are Moving Into Clinical Trials: A Beacon of Hope
The timing of these findings could not be more critical for the Phelan-McDermid syndrome community. The landscape of PMS research is rapidly evolving, with several promising clinical trials now underway. These trials are exploring a range of innovative approaches, including precision medicine strategies specifically aimed at addressing the fundamental biology underlying the disorder. Researchers are investigating ways to enhance SHANK3 protein levels, improve synaptic function, or mitigate the effects of its deficiency through various pharmacological and genetic interventions.
For individuals with PMS and their families, receiving a genetic diagnosis now carries far greater significance than ever before. It transcends merely learning the cause of their symptoms; it opens doors to a multifaceted support system and potential pathways to treatment. A confirmed genetic diagnosis can provide access to specialized medical care tailored to the known comorbidities of PMS, allowing for proactive management of associated health issues. Crucially, it provides eligibility for participation in cutting-edge research studies and clinical trials, offering the possibility of being among the first to receive novel, potentially disease-modifying treatments. Moreover, a diagnosis connects families to vital patient support networks, such as the Phelan-McDermid Syndrome Foundation and CureSHANK, which offer invaluable information, emotional support, and advocacy resources, fostering a sense of community and shared understanding.
"This study confirms what many families, clinicians, and advocates have suspected for years," affirmed Geraldine Bliss, CureSHANK Board Chair. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important." Bliss’s statement echoes the urgency felt by the entire PMS community. The potential for these individuals to miss out on life-changing therapies due to a lack of diagnosis is a powerful motivator for increased action.
The results of this prevalence study strongly reinforce CureSHANK’s ongoing efforts to expand access to comprehensive genetic testing. Furthermore, they lend significant weight to the goals of Start Genetic, a global awareness campaign actively encouraging patients, families, healthcare providers, and advocacy groups to adopt a "think genetic first" mindset when evaluating neurodevelopmental disorders. This campaign aims to embed the importance of early genetic diagnosis into standard clinical practice.
Ultimately, the broader message emanating from this research is unequivocal: the revolutionary advances occurring in precision medicine can only reach the patients who need them most if those patients are first accurately identified and diagnosed. This principle holds true not just for Phelan-McDermid syndrome but for the myriad of other rare genetic disorders where targeted interventions are emerging. The journey from scientific discovery to effective therapy is long and complex, but the critical first step—a definitive diagnosis—is now more clearly illuminated than ever before for Phelan-McDermid syndrome. This study marks a pivotal moment, shifting the understanding of PMS from a perceived ultra-rare condition to a more prevalent, yet still significantly underdiagnosed, disorder, thereby accelerating the race towards meaningful therapeutic solutions.
